Initial state | Entered state | HBeAg (+) |  | HBeAg (−) |  | Source |
---|---|---|---|---|---|---|
 |  | Estimate (%) | Range (%) | Estimate (%) | Range (%) |  |
Lamivudine-resistant CHB | Compensated cirrhosis | 2.7 | 1.6-3.8 | 6.2 | 2.8-9.7 | [27] |
 | Hepatocellular carcinoma | 0.4 | 0.3-0.6 | 0.4 | 0.3-0.6 | [27] |
Virological response | Compensated cirrhosis | 0.5 | 0.3-0.8 | 1.2 | 0.7-2 | [25] |
 | Hepatocellular carcinoma | 0.2 | 0.1-0.4 | 0.2 | 0.1-0.4 | [25] |
Multi-resistant CHB | Compensated cirrhosis | 2.7 | 1.6-3.8 | 6.2 | 2.8-9.7 | [27] |
 | Hepatocellular carcinoma | 0.4 | 0.3-0.6 | 0.4 | 0.3-0.6 | [27] |
Compensated cirrhosis | Decompensated cirrhosis | 7.3 | 3.5-10 | 7.3 | 3.5-10 | [28] |
 | Hepatocellular carcinoma | 3.4 | 1-10 | 3.4 | 1-10 | [28] |
 | Death | 4.9 | 2-14 | 4.9 | 2-14 | [28] |
Decompensated cirrhosis | Hepatocellular carcinoma | 3.4 | 1-10 | 3.4 | 1-10 | [28] |
 | Liver transplantation | 5 | 1-10 | 5 | 1-10 | [5] |
 | Death | 14.4 | 10-20 | 14.4 | 10-20 | [5] |
Hepatocellular carcinoma | Liver transplantation | 5 | 1-10 | 5 | 1-10 | [5] |
 | Death | 23.3 | 20-30 | 23.3 | 20-30 | [5] |
Liver transplantation | Death | 7 | 2-12 | 7 | 2-12 | [5] |